Joseph E. Woolery
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lymphoma Diagnosis and Treatment 4
-
- Antifungal resistance and susceptibility 3
- Co-authors
- Myke R. Green (6 shared papers)Daruka Mahadevan (1 shared paper)D-Y. Oh (1 shared paper)E.P. Hamilton (1 shared paper)Lisa Boyken (1 shared paper)Christos Stelios Karapetis (1 shared paper)Hyo Sook Han (1 shared paper)Y-K. Kang (1 shared paper)
- Journals
- Blood (3 papers)Mycoses (1 paper)The Lancet (1 paper)The Lancet Oncology (1 paper)Annals of Oncology (1 paper)
- Partner nations
- United StatesSouth KoreaCanada
In The Last Decade
Joseph E. Woolery
13 papers receiving 891 citations
Joseph E. Woolery's Hit Papers
Peers
Comparison fields: 5 of 55
- Pathology and Forensic Medicine 388
- Oncology 182
- Radiology, Nuclear Medicine and Imaging 77
- Dermatology 27
- Cell Biology 39
Countries citing papers authored by Joseph E. Woolery
This map shows the geographic impact of Joseph E. Woolery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph E. Woolery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph E. Woolery more than expected).
Fields of papers citing papers by Joseph E. Woolery
This network shows the impact of papers produced by Joseph E. Woolery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph E. Woolery. The network helps show where Joseph E. Woolery may publish in the future.
Co-authors
The 25 scholars most cited alongside Joseph E. Woolery, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 561 |
| 2 | 2022 | 147 | |
| 3 | 2011 | 71 | |
| 4 | 2022 | 50 | |
| 5 | 2012 | 27 | |
| 6 | 2011 | 16 | |
| 7 | 2012 | 15 | |
| 8 | 2014 | 7 | |
| 9 | 2010 | 5 | |
| 10 | 2012 | 3 | |
| 11 | 2010 | 2 | |
| 12 | 2012 | 2 | |
| 13 | 2021 | 1 |
About Joseph E. Woolery
Joseph E. Woolery is a scholar working on Pathology and Forensic Medicine, Infectious Diseases, Oncology, Pulmonary and Respiratory Medicine and Hematology, having authored 13 papers that have together received 907 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (4 papers), Antifungal resistance and susceptibility (3 papers), HER2/EGFR in Cancer Research (2 papers), Microtubule and mitosis dynamics (1 paper), Cardiovascular Issues in Pregnancy (1 paper), Acute Myeloid Leukemia Research (1 paper), Electrolyte and hormonal disorders (1 paper) and Cancer Immunotherapy and Biomarkers (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (388 citations), Oncology (182 citations), Radiology, Nuclear Medicine and Imaging (77 citations), Dermatology (27 citations) and Cell Biology (39 citations). Joseph E. Woolery has collaborated with scholars based in United States, South Korea and Canada. Frequent co-authors include Myke R. Green, Daruka Mahadevan, D-Y. Oh, E.P. Hamilton, Lisa Boyken, Christos Stelios Karapetis, Hyo Sook Han, Y-K. Kang, Philippe Lucien Bedard and Komal L. Jhaveri. Their work appears in journals such as Blood, Mycoses, The Lancet, The Lancet Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.